Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase transition ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a strong prognosis predictor for neuroendocrine tumors, according to new research from scientists at the Rigshospitalet, ...

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...

Citi keeps a Buy rating on Exelixis (EXEL) with a $38 price target after the company announced that it has been notified by the FDA that the ...

This new funding positions NRMA Insurance as the first corporate partner to support a McGrath Cancer Care Nurse since the ...

A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung ...